mission

The mission of Late Shri Sitaram Khatore was to relieve the suffering patients from serious liver ailments & jaundice. Khatore pharmaceuticals Pvt. Ltd. (KPPL) was launched in 1984 & since then the company has helped millions of sufferers across the world by providing high quality ayurvedic medicines that meet strict quality standards. Our mission is to continue to help patients globally to manage and recover from liver ailments by providing unique KAMALAHAR as per top quality standards. Also to endeavour for more useful solutions to alleviate mankind's suffering.

patients

research

The CLINICAL TRIALS of Kamalahar were conducted by HOD's and Professors of Departments of Gastroenterology, Medicine & Pharmacology at top medical collages on blind & double-blind randomized methods. The professors published their work in major medical jourals, (JAPI [Two issues], The Indian Practioner, Medical journal of ICMR) The reports may be seen in next section.

Khatore Pharmaceuticals is GMP certified. In recognition of its strict quality assurance and maintenance of high standards, KPPL received the "Best Entrepreneur" award for Ayurvedic Medicine in Asia for the year 2000.

clinical trial

Trial Location : Guntur Medical College and Government General Hospital

No of Participating Patients : 46

Duration : 27th November 1987 to 15th May 1988

PUBLICATIONS



1.Indian Journal of Gastroenterology(1993, October 12(4), 126-8.
2.JAPI(1992)
3.NIH(US National Library of Medicines)

Summary of the Report

Kamalahar showed significantly good results in the treatment of Infective Hepatitis, Anti-tubercular drugs induced jaundice and Alcoholic hepatitis.

Patients with Infective Hepatitis - Patients started the treatment with mean serum bilirubin levels of 8.38 ± 1.02 mg/100 ml. After 5 days of treatment, the serum bilirubin level had fallen to 5.46 ± 0.88 mg/100 ml. After 12 days of treatment, the serum bilirubin levels had fallen to 2.57 ± 0.57 mg/100 ml.

Patients with Anti-tubercular drugs induced jaundice - Patients started the treatment with serum bilirubin levels of 5.6 mg/l00 ml. After 12 days of treatment, the serum bilirubin level had fallen to 2.3 mg/100 ml.

Patients with Alcoholic hepatitis - Patients started the treatment with serum bilirubin levels of 4.75 mg/100 ml. After 12 days of treatment, the serum bilirubin level had fallen to 1.4 mg/100 ml.

Trial Location : M.L.B. Medical College, Jhansi

Duration : 15th June, 1987 to 15th Nov, 1987

No of Participating Patients : 50

Summary of the Report

Published in Indian Medical Practitioner (Bombay), Volume. XLII No 4 Pages (303 - 308)

Kamalahar showed significantly great results in the treatment of Infective Hepatitis, Anti-tubercular drugs induced jaundice and Alcoholic hepatitis. In most of the cases, rise of serum bilirubin was halted on 2nd or 3rd days and the levels dropped to less than 3 mg/100ml by 10th day. Maximum fall of serum bilirubin was noted in between 5th – 10th day of treatment. However, symptomatic improvements, i.e. Nausea, anorexia, vomiting fatigue, responded even earlier.

In one case of alcoholic hepatitis the jaundice subsided in 4 days after treatment with Kamalahar. Two cases who were on anti-tubercular therapy (Rifampicin 450 mg/Isonex 300 mg/ streptomycin 0.75 gm) developed jaundice after 15 days of treatment. Their anti-tubercular drugs (Rifampicin and Isonex) were withdrawn and Kamalahar was started. Their jaundice disappeared in 5-7 days and after 10 days Rifampicin / Isonex were again initiated in low dosage.

Patients with Infective Hepatitis - Patients started the treatment with mean serum bilirubin levels of 8.61+2.49 mg/100ml. After 12 days of treatment, the serum bilirubin levels had fallen to 2.10+1.34 mg/100ml.

Patients with Anti-tubercular drugs induced jaundice - Patients started the treatment with serum bilirubin levels of 6.0+1.41 mg/100ml. After 12 days of treatment, the serum bilirubin level had fallen to less than 1 mg/100 ml.

Patients with Alcoholic hepatitis - Patients started the treatment with serum bilirubin levels of 4.1+0.42 mg/100 ml. After 12 days of treatment, the serum bilirubin level had fallen to less than 1 mg/100 ml.

Trial Location : Indira Gandhi Institute of Medical Sciences, Patna

Duration : May 1987 to Jan 1988

No of Participating Patients : 33

Summary of the Report

Published in JOURNAL OF PHYSICIANS OF INDIA, JAPI, Vol 37, ref abstract page no 64.

The trial was conducted on patients having Acute Viral Hepatitis. Patients treated with Kamalahar showed significantly faster clinical and biochemical recovery as compared to those in placebo group. There was faster decline in the levels of serum bilirubin levels in Kamalahar treated patients. There were no side effects related to the compound. This trial indicates that Kamalahar helps in faster recovery of patients with Acute Viral Hepatitis.

After 2 weeks of treatment with Kamalahar, majority of patients (80%) showed evidence of full clinical and biochemical recovery. Patients started the Kamalahar treatment with mean serum bilirubin levels of 8.6 mg/100 ml. After 1 week of treatment, the serum bilirubin level had fallen to 6.6 mg/100 ml. After 2 weeks of treatment, the serum bilirubin levels had fallen to 3.4 mg/100 ml. After 4 weeks of treatment, the serum bilirubin levels had fallen to 1.4 mg/100 ml.

Trial Location : B. J. Medical College & Civil Hospital, Ahmedabad

Duration : September 1987 to May 1988

No of Participating Patients : 15

Summary of the Report

Published in JOURNAL OF ASSOCIATION OF PHYSICIANS INDIA, JAPI, Vol 39, ISSN 004/5772, refer abstract page no 82.

All patients of Acute Viral Hepatitis (AVH) treated with 10 days course of Kamalahar showed remarkable and rapid symptomatic / clinical improvement. Result revealed rapid biochemical recovery during trials and thereafter, when Kamalahar therapy was discontinued.

All the patients involved in the treatment had classical symptoms of AVH, i.e. loss of appetite, nausea, occasional vomiting, pain in abdomen, generalized weakness, low grade fever with dark urine, yellowish discoloration of sclera and mild to moderate tender hepatomegaly. Within 3-4 days of treatment, marked clinical improvement were observed with a good sense of well being. Almost all the patients were free from their symptoms and signs at the time of discharge with biochemical improvement.

Patients started the Kamalahar treatment with mean serum bilirubin levels of 9.9 mg/100 ml. After 10 days of treatment, the serum bilirubin level had fallen to 4.6 mg/100 ml.